WO2010105636A1 - Topical compositions comprising interleukin-1 alpha and peptides and cosmetic methods thereof - Google Patents
Topical compositions comprising interleukin-1 alpha and peptides and cosmetic methods thereof Download PDFInfo
- Publication number
- WO2010105636A1 WO2010105636A1 PCT/EP2009/001957 EP2009001957W WO2010105636A1 WO 2010105636 A1 WO2010105636 A1 WO 2010105636A1 EP 2009001957 W EP2009001957 W EP 2009001957W WO 2010105636 A1 WO2010105636 A1 WO 2010105636A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- composition
- alpha
- interleukin
- gly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- the present invention relates to topical compositions comprising interleukin-1 alpha in combination with peptides and cosmetic methods thereof.
- Interleukin-1 alpha which is also named IL-IFl, is a naturally occurring polypeptide with the sequence well-known from the art. Umprot/Swiss-prot database #P01583. In norm, interleukin-1 alpha is produced by human epidermis on a constitutive basis. Gahring LC et al., J Clin Invest. 1985, 76(4): 1585. Mizutani H. et a!.. J Clin Invest 1991. 87(3):1066. Hauser C et al.. J Immunol. 1986, 136(9):3317. Upon stimulation with interleukin-1 alpha, dermal fibroblasts produce components of dermis, e.g.
- procollagen, elastin, and hyaluronic acid as well as tools for collagen turnover, e.g. collagenase, inhibitor of the collagenase (TIMP), and inhibitor of procollagen transformation to collagen (PGE2).
- TMP collagenase
- PGE2 procollagen transformation to collagen
- interleukin-1 alpha is a pro-inflammatory cytokine which may induce a sequence of undesirable processes in skin, e.g. edema and redness. It may limit the use of interleukin-1 alpha in cosmetic products.
- a safe and effective agent that can selectively reduce the pro-inflammatory activity of interleukin-1 alpha along with maintaining the interleukin-1 alpha activities related to the dermis remodeling.
- Phe-Leu-Y wherein X is independently GIy, L- or D-AIa; and Y is independently Asp or GIu are useful for selective reducing the pro-inflammatory activity of interleukin-1 alpha along with maintaining the interleukin-1 alpha activities related to the dermis remodeling.
- the structure of the abovementioned hexapeptides is artificial and, while they have similarity with structure of N- terminus of endogenous opioid peptides (beta-endorphin, enkephalins, or dynorphins), they contains uneven for opioid peptides acidic amino acid Asp or GIu at sixth position that determines distinct biological properties with opioid peptides.
- the structure of the hexapeptides is not the same with the structure of N- terminus hexapeptide sequence of endogenous beta-endorphin or dynorphins and the structure contains uneven for beta-endorphin or dynorphins amino acid Asp or GIu at sixth position, the position close to N-terminal conservative motif Tyr-Gly- Gly-Phe-, critical for a peptide binding to opioid receptors.
- the structure of the hexapeptides is not the same with the structure of pentapeptide enkephalins and contains additive acidic amino acid Asp or GIu.
- the hexapeptides Due to the presence of uneven for opioid peptides Asp or GIu in their structure, the hexapeptides becomes acidic and charged negatively at physiological pH, contrary to the enkephalins and other opioid peptides. It produces critical change in the biological activity of the hexapeptides as compared to the biological activity of opioid peptides. In particular, unlike opioid peptides, hexapeptides do not manifest neuronal activity and predominantly observed effect of the hexapeptides is activation of microcirculation in skin.
- interleukin-1 alpha in medicinal applications is known from the art.
- U.S. Patent No. 4,816,436 discloses a process for treating arthritis or inflammation with the use of intra-articular, intramuscular, intravenous, or intraperitoneal injections of interleukin-1 alpha
- U.S. Patent No. 5,120,534 discloses a method for treating thrombocytopenia by administering interleukin-1 alpha or Asp36, Serl 41 -derivative of interleukin-1 alpha
- 5,534,251 discloses stabilized medicinal composition comprising Asp36, Serl41- derivative of interleukin-1 alpha
- EP0391444 discloses a pharmaceutical composition comprising interleukin-1 alpha, and suitable for forming a parenterally administratable aqueous formulation
- WO9116916, JP4018033, EP0482213, and ES2121782T disclose an antitumor composition containing the combination of interleukin-1 and gamma-interferon.
- WO/2006/097359 discloses a composition for treating keratin fibres with aminexil in combination with interleukin-1 alpha taken as NOS synthesis stimulator.
- WO/2005/091891 discloses a method of altering coloration of a tattoo-affected dermal region by interleukin-1.
- topical compositions comprising combination of interleukin-1 alpha with the artificial hexapeptides of the formula Tyr-X-Gly-Phe-Leu-Y, wherein X is independently GIy, L- or D-AIa; and Y is independently Asp or GIu.
- US 2005/0036974 discloses the use of beta-endorphin and beta-endorphin fragments in cosmetic compositions for enhancing barrier function of skin, enhancing moisturizing the skin, strengthening resistance of the skin to stress, pollution, and enhancing brightness of skin.
- topical compositions comprising combination of interleukin-1 alpha with beta-endorphins or beta-endorphin fragments.
- WO/2006/106164 discloses the use of enkephalins for the preparation of a cosmetic or dermatopharmaceutical composition reducing and/or eliminating facial wrinkles.
- topical compositions comprising combination of interleukin-1 alpha with enkephalins.
- US Patent No 5,002,933 discloses a synthetic hexapeptide Tyr-D-Ala-Gly- Phe-Leu-Glu for the use in medicinal preparations for the safe and effective treatment of erosive and ulcerative lesions of the gastrointestinal tract.
- nothing is published or disclosed in the art related to topical compositions comprising combination of interleukin-1 alpha with the hexapeptide Tyr-D-Ala- Gly-Phe-Leu-Glu, or their derivatives, or salts thereof.
- the present invention provides a topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I):
- Tyr-X-Gly-Phe-Leu-Y (I) wherein X is independently GIy, L- or D-AIa; Y is independently Asp or GIu; and a dermatologically acceptable vehicle.
- the hexapeptide is selected from the group consisting of:
- Tyr-Gly-Gly-Phe-Leu-Asp SEQ ID NO: 1
- Tyr-D-Ala-Gly-Phe-Leu-Asp SEQ ID NO: 2
- Tyr-L-Ala-Gly-Phe-Leu-Asp SEQ ID NO: 3
- Tyr-Gly-Gly-Phe-Leu-Glu SEQ ID NO: 4
- Tyr-D-Ala-Gly-Phe-Leu-Glu SEQ ID NO: 5
- Tyr-L-Ala-Gly-Phe-Leu-Glu SEQ ID NO: 6
- the content of interleukin-1 alpha in said compositions is in the range from 10 "7 to 10 ⁇ wt. %.
- the content of the hexapeptide in said composition is in the range from 10 "4 to 10 "1 wt. %.
- compositions further comprise a buffer at a concentration effective to maintain the pH of the composition at between about 4.0 to about 7.5.
- a buffer at a concentration effective to maintain the pH of the composition at between about 4.0 to about 7.5.
- dermatologically or cosmetically acceptable buffers include, but are not limited to, phosphate buffer, acetate, citrate buffer, succinate buffer, and glycine buffer.
- interleukin-1 alpha refers to a protein having the following amino acid sequence and structure (naturally occurring human interleukin-1 alpha), and biologically active analogues and derivatives thereof: Ser-Ala-Pro-Phe-Ser-Phe-Leu-Ser-Asn-Val-Lys-Tyr-Asn-Phe-Met-Arg-Ile-Ile-
- analogue of interleukin-1 alpha refers to an interleukin-1 alpha that contains one or more amino acid substitutions, deletions, additions, or rearrangements compared with human interleukin-1 alpha at sites such that the interleukin-1 alpha analogue still retains the in vivo biological activity of interleukin-1 alpha.
- interleukin-1 alpha analogues include Asp36-interleukin-l alpha and Ser 141 -interleukin-1 alpha.
- Interleukin-1 alpha derivatives include naturally occurring interleukin-1 alpha and interleukin-1 alpha analogues that are chemically or enzymatically derivatized at one or more constituent amino acids, including side chain modifications, backbone modifications, and N-and C- terminal modifications, by for example acetylation, acylation, hydroxylation, methylation, amidation, phosphorylation, pegylation, or glycosylation, and that retain the in vivo biological activity of interleukin-1 alpha.
- An example of an interleukin-1 alpha derivative is N6-myristoyl-Lys 11 -interleukin-1 alpha and HisTag-interleukin-1 alpha.
- topical composition refers to a composition that is applied topically to the human skin, hi this respect, the term “skin” encompasses whole skin or any portion of the skin.
- the term "dermatologically acceptable vehicle” refers to one or more liquid, semi-solid, or solid diluents, which are compatible with interleukin-1 alpha, and are suitable for administration to any portion of the human skin without undue/unacceptable aesthetic effects, e.g., greasiness, color, odor, etc..
- examples of such carriers include, but are not limited to, distilled or deionized water, propyleneglycol, glycerol, and oil.
- the compositions of the present invention can comprise optional ingredients. Such optional ingredients generally are used individually at levels from about 0.0005% to about 10.0%, preferably from about 0.005% to about 1.0% by weight of the composition..
- suitable optional ingredients include, but are not limited to, depigmentation agents; reflectants; humectants; antimicrobial (e.g., antibacterial) agents; UV absorbers; anti-acne agents; anti-aging agents; anti-wrinkling agents, antiseptics; local anesthetics; wound healing promoters; deodorants and antiperspirants; skin emollients and skin moisturizers; tanning agents; skin lightening agents; antifungals; depilating agents; external analgesics; counterirritants; anti-diaper rash agents; make-up preparations; vitamins and nutrients such as thiamin, riboflavin, niacin, pantothenates, pyridoxine, folic acid, cobalamin, biotin, choline, inositol, ascorbic acid, lipoic acid, carnitine, and etc.; amino acids and their derivatives such as alanine, arginine, as
- Suitable reflectants include, but not limited to, mica, alumina, calcium silicate, glycol dioleate, glycol distearate, silica, sodium magnesium fluorosilicate, and mixtures thereof.
- UV absorbers include, but not limited to, benzophenone, bomelone, butyl paba, cinnamidopropyl trimethyl ammonium chloride, disodium distyrylbiphenyl disulfonate, paba, potassium methoxycinnamate, and mixtures thereof.
- humectants include, but not limited to, water soluble liquid polyols selected from the group comprising glycerine, propylene glycol, hexylene glycol, butylene glycol, pentylene glycol, dipropylene glycol, and mixtures thereof.
- the humectant is preferably present in an amount of from about 0 percent to about percent, more preferably from about 0.5 percent to about 5 percent, based on the overall weight of the composition.
- Suitable amino acid agents include amino acids derived from the hydrolysis of various proteins as well as the salts, esters, and acyl derivatives thereof.
- Examples of such amino acid agents nonexclusively include amphoteric amino acids such as alkylamido alkylamines, i.e.
- stearyl acetyl glutamate capryloyl silk amino acid, caprylol collagen amino acids; capryloyl kertain amino acids; capryloyl pea amino acids; cocodimonium hydroxypropyl silk amino acids; corn gluten amino acids; cysteine; glutamic acid; glycine; hair keratin amino acids; hair amino acids such as aspartic acid, threonine, serine, glutamic acid, glycine, alanine, half-cystine, valine, methionine, isoleucine, leucine, tyrosine, phenylalanine, cysteic acid, lysine, histidine, arginine, cysteine, tryptophan, citrulline; lysine; silk amino acids, wheat amino acids; and mixtures thereof [0025]
- suitable proteins include, but not limited to, collagen, deoxyribonuclease, iodized corn protein; keratin;
- Suitable antiperspirants and deodorants include, but not limited to, aluminium chlorohydrates, aluminium zirconium chlorohydrates, and mixtures thereof.
- sunscreen agents include, but not limited to, titanium dioxide and zinc oxide.
- suitable counteri ⁇ tants include, but not limited to, camphor, menthol, methyl salicylate, peppermint and clove oils, ichtammol, and mixtures thereof.
- Suitable anti-aging agents include, but are not limited to, inorganic sunscreens such as zinc oxide; organic sunscreens such as octyl-methyl cinnamates and derivatives thereof; retinoids; vitamins such as vitamin C, vitamin B, and derivatives thereof; antioxidants including acid such as glycolic acid, citric acid, lactic acid, malic acid, mandelic acid, ascorbic acid, alpha-hydroxybutyric acid, alpha-hydroxyisobutyric acid, alpha-hydroxyisocaproic acid, atrrolactic acid, alpha-hydroxyisovaleric acid, ethyl pyruvate, galacturonic acid, glucopehtonic acid, glucopheptono 1,4-lactone, gluconic acid, gluconolactone, glucuronic acid, glucurronolactone, glycolic acid, isopropyl pyruvate, methyl pyruvate, mucic acid, pyruvia acid, saccharic acid
- Suitable depigmentation agents include, but are not limited to, hydroquinone and it derivatives; vitamins such as niacin, vitamin C and its derivatives; extracts such as chamomile and green tea, and mixtures thereof.
- Examples of skin lightening agents include, but not limited to, hydroquinone, catechol and its derivatives, ascorbic acid and its derivatives, and mixtures thereof.
- compositions of the invention are prepared by well-known procedures. Such procedures include, but are not limited to, mixing the interleukin-1 alpha with other ingredients of the composition in conventional manner.
- Guidance for the preparation of cosmetic or dermatological compositions of the invention can be found in " Remington: The science and practice of pharmacy” 20th ed. Mack Publishing, Easton PA, 2000 ISBN 0-912734-04-3 and " Encyclopaedia of Pharmaceutical Technology", edited by Swarbrick, J. & J. C. Boylan, Marcel Dekker, Inc., New York, 1988 ISBN 0-8247-2800-9 or a newer edition.
- illustrative additives to dermatological compositions include, but is not limited to: ointment bases, solvents, buffering agents, pH- adjusting agents, preservatives, humectants, chelating agents, antioxidants, stabilizers, emulsifying agents, suspending agents, gel-forming agents, perfumes, and skin protective agents.
- compositions of the present invention can be formulated in a variety of forms including, but are not limited to, lotions, gels, creams, sprays, and solutions.
- the compositions of the invention are prepared by methods well-known from the art in accordance with accepted procedures in a variety of forms. Such forms include, but are not limited to, solution, lotion, gel, emulsion, spray, and cream.
- the present invention provides a cosmetic method of improving the appearance of wrinkled, lined, dry, aged, photodamaged, cellulite-affected, scar- affected, stretch mark-affected, and/or acne-affected skin, the method comprising the step of applying to the skin of a subject in need thereof the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I):
- Tyr-X-Gly-Phe-Leu-Y (I) wherein X is independently GIy, L- or D-AIa; Y is independently Asp or GIu; and a dermatologically acceptable vehicle.
- the present invention provides a cosmetic method of skin conditioning, the method comprising the step of applying to the skin of a subject in need thereof the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I): Tyr-X-Gly-Phe-Leu-Y (I) wherein X is independently GIy, L- or D-AIa; Y is independently Asp or GIu; and a dermatologically acceptable vehicle.
- the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I): Tyr-X-Gly-Phe-Leu-Y (I) wherein X is independently GIy, L- or D-AIa; Y is independently Asp or GIu; and a dermatologically acceptable vehicle.
- skin conditioning refers to the maintaining the human skin in a good condition, including regulating the skin condition, preventing or reducing visible and/or tactile discontinuities in skin, and/or protecting the skin as it is indicated in European cosmetic legislation.
- the term "regulating skin condition” includes delaying, minimizing and/or preventing visible and/or tactile discontinuities in skin; ameliorating, e.g., diminishing, minimizing and/or effacing, discontinuities in skin; as well as improving skin appearance and/or feel.
- the methods of the present invention are particularly advantageous for maintenance of aged skin in good condition, including regulating signs of skin aging, more especially visible and/or tactile discontinuities in skin texture associated with aging.
- Regulation the signs of skin aging includes regulating one or more of such signs, e.g., lines, wrinkles or pores.
- regulating such signs includes delaying, minimizing and/or preventing signs of skin aging; as well as ameliorating, e.g., diminishing, minimizing and/or effacing signs of skin aging.
- “Signs of skin aging” include, but are not limited to, all outward visibly and tactilely perceptible manifestations as well as any other macro or micro effects due to skin aging.
- Such signs may be induced or caused by intrinsic factors or extrinsic factors, e.g., chronological aging and/or environmental damage. These signs may result from processes which include, but are not limited to, the development of textural discontinuities such as wrinkles, including both fine superficial wrinkles and coarse deep wrinkles, skin lines, crevices, bumps, large pores (e.g., associated with adnexal structures such as sweat gland ducts, sebaceous glands, or hair follicles), scaliness, flakiness and/or other forms of skin unevenness or roughness, loss of skin elasticity (loss and/or inactivation of functional skin elastin), sagging (including puff ⁇ ness in the eye area and jowls), loss of skin firmness, loss of skin tightness, loss of skin recoil from deformation, discoloration (including undereye circles), blotching, sallowness, hyperpigmented skin regions such as age spots and freckles, keratoses, abnormal differentiation, hyperkeratin
- the present invention provides a cosmetic method of reducing wrinkles, the method comprising the step of applying to the skin of a subject in need thereof the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I): Tyr-X-Gly-Phe-Leu-Y (I) wherein X is independently GIy, L- or D-AIa; Y is independently Asp or GIu; and a dermatologically acceptable vehicle.
- the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I): Tyr-X-Gly-Phe-Leu-Y (I) wherein X is independently GIy, L- or D-AIa; Y is independently Asp or GIu; and a dermatologically acceptable vehicle.
- the present invention provides a cosmetic method of improving skin elasticity and firmness, the method comprising the step of applying to the skin of a subject in need thereof the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I):
- the present invention provides a cosmetic method of reducing cellulite severity, the method comprising the step of applying to the skin of a subject in need thereof the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (T):
- Tyr-X-Gly-Phe-Leu-Y (I) wherein X is independently GIy, L- or D-AIa; Y is independently Asp or GIu; and a dermatologically acceptable vehicle.
- cellulite refers to visible and tactile irregularities of skin caused by irregularities of subcutaneous tissue, also is named as orange peel, gynoid lipodystrophy, and etc. Cellulite is frequently accompanied with an increase in regional fat at the cellulite-affected area and is caused by irregularity of dermis- hypodermis junction and fat protrusions to the lower dermis giving rise to visible irregularity at skin surface.
- cellulite severity refers to the extent of skin irregularity and can be estimated by a skilled artisan or instrumental methods as it described in public domain, for example, by Smalls LK et al., J Cosmet Sci, 2005, 56(2): 105.
- reducing cellulite severity means reducing visible or tactile irregularity of skin surface at cellulite-affected skin area.
- the present invention provides a cosmetic method of enhancing collagen and elastin production in skin, the method comprising the step of applying to the skin of a subject in need thereof the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I):
- the present invention provides a cosmetic method of reducing stretch marks, the method comprising the step of applying to the skin of a subject in need thereof the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I):
- Tyr-X-Gly-Phe-Leu-Y (I) wherein X is independently GIy, L- or D-AIa; Y is independently Asp or GIu; and a dermatologically acceptable vehicle.
- the present invention provides a cosmetic method of reducing reducing and/or preventing scars, the method comprising the step of applying to the skin of a subject in need thereof the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I):
- Tyr-X-Gly-Phe-Leu-Y (I) wherein X is independently GIy, L- or D-AIa; Y is independently Asp or GIu; and a dermatologically acceptable vehicle.
- scar refers to any visible and/or tactile discontinues of a skin resulted from the undesirable overproduction of fibrous tissue during a wound healing process, accompanied with acne, trauma, and surgery including plastic surgery.
- the present invention provides use of the topical composition comprising interleukin-1 alpha and a hexapeptide of the general formula (I): Tyr-X-Gly-Phe-Leu-Y (I) wherein X is independently GIy, L- or D-AIa; Y is independently Asp or GIu; and a dermatologically acceptable vehicle for the preparation of a cosmetic product for skin conditioning, reducing cellulite severity, improving skin elasticity and firmness, reducing wrinkles, enhancing collagen and elastin production in skin, reducing stretch marks, and/or reducing or preventing scars.
- a cosmetic product for skin conditioning, reducing cellulite severity, improving skin elasticity and firmness, reducing wrinkles, enhancing collagen and elastin production in skin, reducing stretch marks, and/or reducing or preventing scars.
- an effective amount of the composition of the invention is topically applied to the skin, and is preferably left on the skin for a period of at least about 15 minutes, more preferably at least about 30 minutes, even more preferably at least about 1 hour, most preferably for at least several hours, e.g., up to about 12 hours.
- This method can be reapplied from 1 to about 5, preferably from 1 to 3 times per day.
- the effective amount of the composition is from about 1 gram to about 100 grams, preferably from about 1 gram to about 20 grams.
- the peptides having an amino acid sequences of SEQ ID NO: 1 through 6 were prepared by solid-phase peptide synthesis (SPPS) technique using Applied Biosystems 430A Peptide Synthesizer following the instructions provided in the instruction manual supplying by the manufacturer.
- SPPS solid-phase peptide synthesis
- This example demonstrates the efficacy of hexapeptides of SEQ ID NO: 1 through 6 to inhibit pro-inflammatory action of interleukin-1 alpha.
- This example demonstrates the efficacy of hexapeptides to inhibit undesirable effects of interleukin-1 alpha under topical applications.
- a water solution of 1 ⁇ g/ml interleukin-1 alpha with or without of 100 ⁇ g/ml peptide of SEQ ID NO: 2 were applied to a skin surface of volunteers.
- the composition comprising the peptide SEQ ID NO: 2 does not induce any irritation-like feeling on the skin.
- the composition comprising the hexapeptides in combination with interleukin-1 alpha provides particularly advanced properties as compared to the composition without the hexapeptides.
- composition preparation ingredients are mixed in the conventional manner to prepare the composition.
- 1 ml of the composition is topically applied to the facial skin, and is preferably left on the skin for a period of at least about 15 minutes.
- Example 5 This example demonstrates the cosmetic methods of the present invention.
- composition of example 4 was applied twice-a-day for eight weeks to the cellulite-affected skin region of thighs of fifteen women aged > 35 years with body fat index (BFI) > 25 (33.9 ⁇ 0.9).
- Efficacy of the composition for reducing cellulite severity was assessed by measurements of irregularity of dermis and dermis-hypodermis junction surface by ultrasonography, using a Dermascan® device at 20-Mhz frequency. Smalls LK et a!.. Quantitative model of cellulite: three-dimensional skin surface topography, biophysical characterization, and relationship to human perception. J Cosmet Sci. 2005, 56(2): 105-20.
- the efficacy of the composition for improving skin elasticity and firmness was assessed by a suction method, using a Cutometer®.
- the efficacy of the composition for keeping a skin in a good condition, or skin conditioning efficacy was assessed by transepidermal water loss (TEWL), using a Tewameter®.
- the efficacy of the composition for enhancing collagen and elastin production was assessed by ultrasonography, using a Dermascan® device at 20-Mhz frequency. Results obtained at eight week of the treatment are presented in the Table below in percent of changes of mean to basal level (just before the treatment).
- Example 6 shows that topical applying the composition of present invention is effective for reducing severity of cellulite, enhancing collagen and elastin production in skin, improving skin elasticity and firmness, and keeping the skin in a good condition.
- Example 6 shows that topical applying the composition of present invention is effective for reducing severity of cellulite, enhancing collagen and elastin production in skin, improving skin elasticity and firmness, and keeping the skin in a good condition.
- the composition of example 4 was applied twice-a-day for eight weeks to the aging sign-affected skin regions of faces of ten women aged > 45 years.
- the efficacy of the composition for the reducing signs of aging skin was assessed by a battery of tests.
- Skin substructure (epidermis plus dermis thickness, dermis density, and collagen) was assessed by ultrasonography, using Dermascan® device with 20-Mhz frequency.
- Micro-wrinkles deepness and orientation were assessed by profilometry. Deep wrinkles were assessed by laser profilometry on silicon prints.
- the efficacy of the composition for improving skin elasticity and firmness was assessed by a suction method, using a Cutometer® .
- the efficacy of the composition for keeping a skin in a good condition, or skin conditioning efficacy was assessed by transepidermal water loss (TEWL), using a Tewameter®. Results obtained at eight week of the treatment are presented in the Table below in percent of changes of mean to basal level (just before the treatment).
- the example shows that topical applying the composition of present invention is effective for reducing wrinkles, enhancing collagen and elastin production in skin, improving skin elasticity and firmness, and keeping the skin in a good condition.
- Example 7 This example demonstrates the cosmetic methods of the present invention.
- Example 8 This example demonstrates the cosmetic methods of the present invention.
- composition of example 4 Three women having the stretch marks after the pregnancy applied the composition of example 4 onto the stretch marks for eight weeks. It was found that the applying the composition reduced stretch marks as compared to baseline. Thus, the example shows that topical applying the composition of present invention is effective for reducing stretch marks.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0924416A BRPI0924416B1 (en) | 2009-03-17 | 2009-03-17 | topical composition and cosmetic methods for improving appearance and firmness and elasticity, conditioning, reducing the severity of cellulite, stretch marks and wrinkles, reducing and / or preventing scars, increasing collagen and elastin production of the skin and use of composition. |
MX2011009572A MX2011009572A (en) | 2009-03-17 | 2009-03-17 | Topical compositions comprising interleukin-1 alpha and peptides and cosmetic methods thereof. |
PCT/EP2009/001957 WO2010105636A1 (en) | 2009-03-17 | 2009-03-17 | Topical compositions comprising interleukin-1 alpha and peptides and cosmetic methods thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2009/001957 WO2010105636A1 (en) | 2009-03-17 | 2009-03-17 | Topical compositions comprising interleukin-1 alpha and peptides and cosmetic methods thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010105636A1 true WO2010105636A1 (en) | 2010-09-23 |
WO2010105636A8 WO2010105636A8 (en) | 2010-11-11 |
Family
ID=42536333
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/001957 WO2010105636A1 (en) | 2009-03-17 | 2009-03-17 | Topical compositions comprising interleukin-1 alpha and peptides and cosmetic methods thereof |
Country Status (3)
Country | Link |
---|---|
BR (1) | BRPI0924416B1 (en) |
MX (1) | MX2011009572A (en) |
WO (1) | WO2010105636A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016141498A1 (en) * | 2015-03-11 | 2016-09-15 | Rodriguez Cerda Patricio Alfredo | Topically applied cosmetic reductive composition containing keratin and sulphur |
CN108290926A (en) * | 2016-06-07 | 2018-07-17 | 江苏恒瑞医药股份有限公司 | Phenylpropionyl amine derivant, preparation method and its application in medicine |
RU2664702C1 (en) * | 2017-03-10 | 2018-08-21 | Сергей Георгиевич Морозов | Method of prophylaxis of failure of the interintestinal anastomosis in surgery in the abdominal cavity by the peptide |
WO2021033829A1 (en) * | 2019-08-20 | 2021-02-25 | (주)케어젠 | Peptide having activity of improving skin condition and use thereof |
WO2023184114A1 (en) * | 2022-03-28 | 2023-10-05 | 深圳市维琪科技股份有限公司 | Polypeptide and cosmetic composition or pharmaceutical composition and use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0391444A2 (en) * | 1989-04-07 | 1990-10-10 | Syntex (U.S.A.) Inc. | Interleukin-1 Formulation |
US5002933A (en) * | 1987-06-19 | 1991-03-26 | Vinogradov Valentin A | Hexapeptide and medicinal preparation produced from it to treat erosive and ulcerative lesions of gastrointestinal tract |
US20050036974A1 (en) * | 2003-07-17 | 2005-02-17 | L'oreal | Beta-endorphin activity in cosmetics and dermatology |
EP1892247A1 (en) * | 2005-04-08 | 2008-02-27 | Lipotec, S.A. | Dermopharmaceutical or cosmetic composition comprising enkephalin-derived peptides for reducing and/or eliminating facial wrinkles |
WO2010051852A1 (en) * | 2008-11-07 | 2010-05-14 | United Technologies Ut Ag | Compositions containing interleukin-1 and peptides |
-
2009
- 2009-03-17 MX MX2011009572A patent/MX2011009572A/en active IP Right Grant
- 2009-03-17 BR BRPI0924416A patent/BRPI0924416B1/en active IP Right Grant
- 2009-03-17 WO PCT/EP2009/001957 patent/WO2010105636A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5002933A (en) * | 1987-06-19 | 1991-03-26 | Vinogradov Valentin A | Hexapeptide and medicinal preparation produced from it to treat erosive and ulcerative lesions of gastrointestinal tract |
EP0391444A2 (en) * | 1989-04-07 | 1990-10-10 | Syntex (U.S.A.) Inc. | Interleukin-1 Formulation |
US20050036974A1 (en) * | 2003-07-17 | 2005-02-17 | L'oreal | Beta-endorphin activity in cosmetics and dermatology |
EP1892247A1 (en) * | 2005-04-08 | 2008-02-27 | Lipotec, S.A. | Dermopharmaceutical or cosmetic composition comprising enkephalin-derived peptides for reducing and/or eliminating facial wrinkles |
WO2010051852A1 (en) * | 2008-11-07 | 2010-05-14 | United Technologies Ut Ag | Compositions containing interleukin-1 and peptides |
Non-Patent Citations (3)
Title |
---|
BLANES-MIRA C ET AL: "A SYNTHETIC HEXAPEPTIDE (ARGIRELINE) WITH ANTIWRINKLE ACTIVITY", INTERNATIONAL JOURNAL OF COSMETIC SCIENCE, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL LNKD- DOI:10.1046/J.1467-2494.2002.00153.X, vol. 24, no. 5, 1 January 2002 (2002-01-01), pages 303 - 310, XP009045291, ISSN: 0142-5463 * |
DATABASE BIOSIS, [online] 1 January 1987 (1987-01-01), VINOGRADOV V A ET AL: "OPIOID ACTIVITY OF PEPTIDES AND SKIN WOUND HEALING", XP002509588, retrieved from BIOSIS * |
DATABASE CAPLUS, [online] 27 October 2006 (2006-10-27), KIPPER S N: "Cream for sensitive skin", XP002530287, retrieved from CAPLUS * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016141498A1 (en) * | 2015-03-11 | 2016-09-15 | Rodriguez Cerda Patricio Alfredo | Topically applied cosmetic reductive composition containing keratin and sulphur |
US10245224B2 (en) | 2015-03-11 | 2019-04-02 | Patricio Alfredo Rodriguez Cerda | Topically applied cosmetic reductive composition containing keratin and sulphur |
CN108290926A (en) * | 2016-06-07 | 2018-07-17 | 江苏恒瑞医药股份有限公司 | Phenylpropionyl amine derivant, preparation method and its application in medicine |
EP3466962A4 (en) * | 2016-06-07 | 2020-01-08 | Jiangsu Hengrui Medicine Co., Ltd. | Phenyl propanamide derivative, and manufacturing method and pharmaceutical application thereof |
RU2738207C2 (en) * | 2016-06-07 | 2020-12-09 | Цзянсу Хэнжуй Медицин Ко., Лтд. | Phenylpropanamide derivative, a method for production thereof and pharmaceutical use thereof |
CN108290926B (en) * | 2016-06-07 | 2022-02-08 | 江苏恒瑞医药股份有限公司 | Phenyl propionamide derivative, preparation method and medical application thereof |
RU2664702C1 (en) * | 2017-03-10 | 2018-08-21 | Сергей Георгиевич Морозов | Method of prophylaxis of failure of the interintestinal anastomosis in surgery in the abdominal cavity by the peptide |
WO2021033829A1 (en) * | 2019-08-20 | 2021-02-25 | (주)케어젠 | Peptide having activity of improving skin condition and use thereof |
WO2023184114A1 (en) * | 2022-03-28 | 2023-10-05 | 深圳市维琪科技股份有限公司 | Polypeptide and cosmetic composition or pharmaceutical composition and use thereof |
CN117203217A (en) * | 2022-03-28 | 2023-12-08 | 深圳市维琪科技股份有限公司 | Polypeptide and cosmetic composition or medicinal composition and application thereof |
Also Published As
Publication number | Publication date |
---|---|
MX2011009572A (en) | 2011-09-28 |
WO2010105636A8 (en) | 2010-11-11 |
BRPI0924416A8 (en) | 2015-12-22 |
BRPI0924416B1 (en) | 2017-06-06 |
BRPI0924416A2 (en) | 2015-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101045658B1 (en) | Compositions Comprising Tetrapeptide and Tripeptide Mixtures | |
US8298523B2 (en) | Compositions containing interleukin-1 and peptides | |
ES2421262T3 (en) | Composition for personal and cosmetic care containing tetrapeptides with CX1X2G, PX1X2P or PX1X2K units | |
EP1885741B1 (en) | Lys-thr dipeptides and their use | |
WO2010105636A1 (en) | Topical compositions comprising interleukin-1 alpha and peptides and cosmetic methods thereof | |
CA2839634C (en) | Methods for the production of a cosmetic composition comprising leukolectin and uses thereof | |
CN116143873A (en) | Active peptide and application thereof in preparation of anti-skin-aging drugs or cosmetics | |
WO2010105634A1 (en) | Use of interleukin-1 beta in cosmetic compositions and methods thereof | |
US20060293227A1 (en) | Cosmetic compositions and methods using transforming growth factor-beta mimics | |
JP2019523300A (en) | Skin care products and their use | |
US7981409B2 (en) | Method of reducing aging of skin by applying interleukin-1 alpha | |
US8603456B2 (en) | Method of treating hair loss with compositions containing interleukin-1 | |
WO2009129857A1 (en) | Hexapeptides and compositions thereof | |
WO2009093925A1 (en) | COSMETIC COMPOSITIONS COMPRISING 5-AMINO-L-β-D- RIBOFURANOSYL-LH-IMIDAZOLE-4-CARBOXAMIDE OR DERIVATIVES, OR SALTS THEREOF | |
WO2023233383A2 (en) | Topical composition for homeostatic delivery of nitric oxide and uses thereof | |
CN113491643A (en) | Antipruritic use of angiogenin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09776445 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1695/MUMNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/009572 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09776445 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0924416 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: PI0924416 Country of ref document: BR Free format text: COM BASE NA RESOLUCAO 228/09 SOLICITA-SE QUE SEJAM APRESENTADOS NOVOS CDS/DVDS, POIS O ARQUIVO DA LISTAGEM DE SEQUEENCIA NAO FOI APRESENTADO NO FORMATO TXT. |
|
ENP | Entry into the national phase |
Ref document number: PI0924416 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110906 |